Cantor Fitzgerald initiated coverage of Coincheck (CNCK) with an Overweight rating and $10 price target Coincheck, a Japanese cryptocurrency ...
Cantor Fitzgerald analyst Deepak Mathivanan maintained a Buy rating on Pinterest (PINS – Research Report) today and set a price target of $48.00. The company’s shares closed yesterday at $33.59.
billionaire chairman and CEO of Wall Street firm Cantor Fitzgerald, to run the Commerce Department. The Senate Commerce Committee voted 16-12 with all Democrats except Senator John Fetterman ...
https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-price-target-raised-to-450-from-433-at-scotiabank Cantor Fitzgerald raised the firm’s price target on ...
On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Surgery Partners (NASDAQ:SGRY) with a steady price target of $36.00. The stock, which has shown significant momentum with a 20% ...
On Friday, Cantor Fitzgerald reaffirmed its Overweight rating on Cipher Mining shares (NASDAQ:CIFR), with a set price target of $11.00. The firm's analyst, Brett Knoblauch, provided insight into ...
Fintel reports that on January 30, 2025, Cantor Fitzgerald upgraded their outlook for Lam Research (WBAG:LRC2) from Neutral to Overweight. There are 1,883 funds or institutions reporting positions ...
Cantor Fitzgerald CEO and Commerce Secretary nominee Howard Lutnick became visibly emotional at his confirmation hearing Wednesday as he recalled the more than 650 employees — including his ...
Eric Johnston, senior managing director at Cantor Fitzgerald, said he is bullish China equities (NYSEARCA:FXI), (MCHI), (GXC) in its bi-weekly equity and macro trading presentation. Cantor ...
This month, Flagstar offloaded $142 million of that portfolio, finding a buyer in Howard Lutnick’s Cantor Fitzgerald, PincusCo reported. A spokesperson for Cantor Fitzgerald did not return a ...
On Monday, Cantor Fitzgerald analysts provided insights into mobility stocks with a focus on Tesla (NASDAQ:TSLA), as the electric vehicle giant gears up to release its earnings report later this week.
Cantor Fitzgerald currently has a “Overweight” rating and a $30.00 price target on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.58) per share ...